Nature Reviews Drug Discovery contents March 2014 Volume 13 Number 3 pp 157 - 236

If you are unable to see the message below, click here to view.

Advertisement
Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants  Newer antidepressants are needed for the many individuals with major depressive disorder that do not respond adequately to treatment and because of a delay of weeks before the emergence of therapeutic effects. In this review, Caroline A. Browne and Irwin Lucki examine the preclinical literature attempting to model the antidepressant-like effects of ketamine. Read more articles from Frontiers in Pharmacology
TABLE OF CONTENTS
March 2014 Volume 13 Number 3
Impact Factor 33.078 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Drugging the p53 pathway: understanding the route to clinical efficacy Khoo Kian Hoe, Chandra S. Verma & David P. Lane
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
The Structural Genomics Consortium (SGC), Natureconferences, and the São Paulo Research Foundation are pleased to present: Chemical Probe-based Open Science: Uncovering New Human and Plant Biology April 28-29, 2014 Faculdade de Ciências Médicas, State University of Campinas (UNICAMP), Brazil  Click here for more information or to register for this conference today!
In this issue p157 | doi:10.1038/nrd4256 Full Text
Comment: Policies to aid the adoption of personalized medicine Charity Nofziger, Marisa Papaluca, Andre Terzic, Scott Waldman & Markus Paulmichl p159 | doi:10.1038/nrd4257 Recent policy developments in the European Union and elsewhere aim to tackle some of the key issues responsible for the limited adoption of personalized medicine approaches so far. Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
Built-to-buy start-ups begin to bloom Asher Mullard p161 | doi:10.1038/nrd4258 A new model of company creation pioneered by Lilly, Celgene, Sanofi, Roche and others is set to deliver both clinical candidates and platform technologies. PDF
Kinase inhibitors overachieve in CLL Ken Garber p162 | doi:10.1038/nrd4259 Chronic lymphocytic leukaemia (CLL) has become a fertile testing ground for novel targeted agents, one of which may become the most lucrative haematology drug in history. PDF
NEWS IN BRIEF FDA dissects 12 years of complete response letters p165 | doi:10.1038/nrd4272 PDF
An antibiotic comeback? p165 | doi:10.1038/nrd4273 PDF
The BACE race is on p165 | doi:10.1038/nrd4274 PDF
BIOBUSINESS BRIEFS Trail watch: Global migration of clinical trials Paul K. Drain, Marion Robine, King K. Holmes & Ingrid V. Bassett p166 | doi:10.1038/nrd4260 PDF
PATENT WATCH Patentee bears burden of proof when licence agreements are questioned Charlotte Harrison p168 | doi:10.1038/nrd4276 PDF
Recent patents related to p53 p169 | doi:10.1038/nrd4277 PDF
AN AUDIENCE WITH John Reed p170 | doi:10.1038/nrd4262 John Reed, Head of Pharma Research & Early Development at Roche, discusses his plans to tweak the therapeutic focus, clinical development strategy and externalization of innovation at Roche. PDF
FROM THE ANALYST'S COUCH Systemic lupus erythematosus and lupus nephritis Toli Koutsokeras & Tina Healy p173 | doi:10.1038/nrd4227 The late-stage pipeline for systemic lupus erythematosus (SLE) and lupus nephritis (LN) contains biologics and small-molecule drugs for a broad range of different targets. Koutsokeras and Healy discuss their likely impact on the future SLE and LN market. PDF
RESEARCH HIGHLIGHTS Top Inflammatory disorders: Monocytes derailed by microparticles p175 | doi:10.1038/nrd4263 PDF Vascular disease: A new way to starve vascular endothelial cells p176 | doi:10.1038/nrd4264 PDF Anticancer drugs: A clearer pathway view p176 | doi:10.1038/nrd4267 PDF Neurological disorders: Presynaptic glycine receptors become a startling target p177 | doi:10.1038/nrd4265 PDF Antibody engineering: Fine-tuning antibody-drug conjugates p178 | doi:10.1038/nrd4266 PDF IN BRIEF Anticancer drugs: Double boost for doxorubicin therapy | Epigenetics: Banishing bad memories | Target identification: Targeting neuronal loss in Gaucher's disease | Autoimmune disease: Antidiabetic mechanisms uncovered PDF Drug Discovery JOBS of the week Postdoc Cancer Biology for Drug Discovery Italian Institute of Technology (ITT) Tier 2 Canada Research Chair in Molecular Pharmacology and Drug Discovery University of Ottawa Postdoctoral Fellow In Biomarker Discovery In Prostate Cancer University of California - San Francisco Research Associate Ontario Institute for Cancer Research PhD (graduate) student University of Lausanne (UNIL) More Science jobs from Drug Discovery EVENT Alzheimer's Research UK Drug Discovery Institute 20.11.14 UK More science events from
PERSPECTIVES		Top
OPINION Targeting tumour-supportive cellular machineries in anticancer drug development Matthias Dobbelstein & Ute Moll p179 | doi:10.1038/nrd4201 Agents that target tumour-supportive cellular machineries, such as the proteasome, heat shock protein complexes and proteins involved in chromatin modifications, are emerging as a new wave of anticancer drugs. Here, Dobbelstein and Moll provide their perspective on the advantages and limitations of these agents compared with established drugs that target DNA replication or signalling proteins such as kinases. Abstract | Full Text | PDF
REVIEWS		Top
REV-ERB and ROR nuclear receptors as drug targets Douglas J. Kojetin & Thomas P. Burris p197 | doi:10.1038/nrd4100 This Review highlights recent progress in the development of ligands to target two classes of nuclear receptors — the REV-ERBs and retinoic acid receptor-related orphan receptors (RORs) — and describes how such ligands might be useful for treating disorders related to metabolism, immune function and the circadian rhythm. Abstract | Full Text | PDF
Drugging the p53 pathway: understanding the route to clinical efficacy Khoo Kian Hoe, Chandra S. Verma & David P. Lane p217 | doi:10.1038/nrd4236 The tumour suppressor p53 is the most frequently mutated gene in human cancer, and drugs that restore or activate the p53 pathway have now reached clinical trials. Most of these drugs inhibit MDM2, a negative regulator of p53. In this Review, Lane and colleagues provide an overview of the different therapeutic approaches to targeting the p53 pathway and discuss the state of development of p53 pathway modulators. Abstract | Full Text | PDF
Advertisement
nature.com webcasts Macmillan Science Communication presents a custom webcast: Biomarkers and immunoassays: Enhancing your research with multiplex cytokine profiling. Thursday 20 March at 8am PDT / 11am EDT / 3pm GMT / 4pm CET Register for the free webcast followed by a live Q & A session  Sponsored by:
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.